KCT0006973
Untitled Trial
Window of opportunity trial of durvalumab (MEDI4736) to identify immune dynamics in operable non-small cell lung cancer (NSCLC) (MIRACLE)
Yonsei University Health System, Severance Hospital·Phase 2·Korean Clinical Trial RegistryNot yet recruiting
Study focus
- Disease/Condition
- Non-small cell lung cancer
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Yonsei University Health System, Severance Hospital
- Funder
- AstraZeneca Korea
- Location
- South Korea
Timeline & enrollment
- Phase
- Phase 2
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
- Registry
- Korean Clinical Trial Registry
- Trial ID
- KCT0006973
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for KCT0006973 through Pure Global AI's free database. This Phase 2 trial is sponsored by Yonsei University Health System, Severance Hospital and is currently Not yet recruiting. The study focuses on Non-small cell lung cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Korean Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.